FIBCD1

Across TCGA pan-cancer cohorts, FIBCD1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FIBCD1 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher FIBCD1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FIBCD1 expression acts as an unfavorable survival marker.

ACC, UCEC, and LGG are the cancer types where FIBCD1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.046	0.753	<.001	36	view →
UCEC	OS	Median	III,IV	0.061	0.588	.018	12	view →
LGG	DFS	Median	All	0.110	0.833	<.001	6	view →
SKCM	DFS	Median	All	0.285	0.641	.020	4	view →
SARC	DFS	Median	All	0.121	0.591	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FIBCD1–ACC (DFS)

Open the ACC breakdown →